Danhong injection in the treatment of chronic stable angina: study protocol for a randomized controlled trial

Peng Qian Wang, Dan Dan Li, Wei Dong, Jun Liu, Ya Nan Yu, Chun Ti Shen, Qi Guang Chen, Bing Wei Chen, Yun Dai Chen, Zhong Wang, Peng Qian Wang, Dan Dan Li, Wei Dong, Jun Liu, Ya Nan Yu, Chun Ti Shen, Qi Guang Chen, Bing Wei Chen, Yun Dai Chen, Zhong Wang

Abstract

Background: Chronic stable angina is a leading cause of death worldwide. Danhong injection, a complementary alternative medicine for chronic stable angina, has been demonstrated to be effective in numerous studies and is widely prescribed to patients. However, the methodological quality of most prior studies was found to be, in general, low. Therefore, we designed this randomized controlled trial to evaluate the efficacy and safety of using Danhong injection to treat chronic stable angina.

Methods/design: This is a randomized multicentre, double-blind, placebo-controlled, adaptive clinical trial. A total of 870 patients meeting the eligibility criteria will be randomly assigned into either the Danhong injection or the placebo group in a 2:1 ratio. Participants will then undergo a 2-week treatment regimen and a 76-day follow-up period. Because this is an adaptive trial, two interim analyses are prospectively planned. These will be performed after one-third and two-thirds of the patients, respectively, have completed the trial. Based on the results of these interim analyses, a data monitoring committee will determine how to modify aspects of the study without undermining the validity and integrity of the trial. The primary outcome measure is the proportion of patients who show a clinically significant change, which is defined as at least a 20-point improvement in angina frequency score on the Seattle Angina Questionnaire, which will be administered on day 30. Other secondary efficacy and safety outcomes will also be assessed.

Discussion: This trial will provide high-quality evidence regarding the use of Danhong injection to treat chronic stable angina.

Trial registration: ClinicalTrials.gov: NCT01681316 .

Figures

Fig. 1
Fig. 1
Trial flow chart: DMC, data monitoring committee

References

    1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Executive summary: heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation. 2014;129:399–410. doi: 10.1161/01.cir.0000442015.53336.12.
    1. Wilson JF. In the clinic: stable ischemic heart disease. Ann Intern Med. 2014;160(ITC1):1–16.
    1. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012;126:3097–137. doi: 10.1161/CIR.0b013e3182776f83.
    1. Navarese EP, Kowalewski M, Suryapranata H. Percutaneous coronary intervention vs medical treatment in stable angina: the never-ending story. JAMA Int Med. 2014;174:1199–200. doi: 10.1001/jamainternmed.2014.1529.
    1. Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R, et al. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014;371:1091–9. doi: 10.1056/NEJMoa1406430.
    1. Wiest FC, Bryson CL, Burman M, McDonell MB, Henikoff JG, Fihn SD. Suboptimal pharmacotherapeutic management of chronic stable angina in the primary care setting. Am J Med. 2004;117:234–41. doi: 10.1016/j.amjmed.2004.02.044.
    1. Kirwan BA, Lubsen J, Poole-Wilson PA. Treatment of angina pectoris: associations with symptom severity. Int J Cardiol. 2005;98:299–306. doi: 10.1016/j.ijcard.2003.10.050.
    1. Borrás X, Garcia-Moll X, Gómez-Doblas JJ, Zapata A, Artigas R, AVANCE study researchers Stable angina in Spain and its impact on quality of life. The AVANCE registry. Rev Esp Cardiol (Engl Ed) 2012;65:734–41. doi: 10.1016/j.recesp.2012.03.011.
    1. Xiong XJ, Wang Z, Wang J. Innovative strategy in treating angina pectoris with Chinese patent medicines by promoting blood circulation and removing blood stasis: experience from combination therapy in Chinese medicine. Curr Vasc Pharmacol. 2014;10:15.
    1. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med. 2007;356:830–40. doi: 10.1056/NEJMra061889.
    1. Wood MJ, Stewart RL, Merry H, Johnstone DE, Cox JL. Use of complementary and alternative medical therapies in patients with cardiovascular disease. Am Heart J. 2003;145:806–12. doi: 10.1016/S0002-8703(03)00084-X.
    1. Su D, Li L. Trends in the use of complementary and alternative medicine in the United States: 2002–2007. J Health Care Poor Underserved. 2011;22:296–310.
    1. Gao ZY, Xu H, Shi DZ, Wen C, Liu BY. Analysis on outcome of 5,284 patients with coronary artery disease: the role of integrative medicine. J Ethnopharmacol. 2012;141:578–83. doi: 10.1016/j.jep.2011.08.071.
    1. Chen KJ, Shi DZ, Xu H, Lv SZ, Li TC, Ke YN, et al. XS0601 reduces the incidence of restenosis: a prospective study of 335 patients undergoing percutaneous coronary intervention in China. Chin Med J. 2006;119:6–13.
    1. Wang J, Xiong X. Current situation and perspectives of clinical study in integrative medicine in China. Evid Based Complement Alternat Med. 2012;2012:1–11.
    1. Luo J, Shang Q, Han M, Chen K, Xu H. Traditional Chinese medicine injection for angina pectoris: an overview of systematic reviews. Am J Chin Med. 2014;42:37–59. doi: 10.1142/S0192415X14500037.
    1. Zhang Z, Zhang F, Wang Y, Du Y, Zhang H, Kong D, et al. Traditional Chinese medicine for stable angina pectoris via TCM pattern differentiation and TCM mechanism: study protocol of a randomized controlled trial. Trials. 2014;15:e422,1–8.
    1. Sun K, Fu C, Nie S, You Y. The index and improvement effect of using Danhong injection to patients with atherosclerosis symptoms of coronary heart disease (CHD) Pak J Pharm Sci. 2014;27(Suppl 5):1699–704.
    1. Du J, Yang W, Yi D, Xie Y, Yang W, Zhuang Y, et al. Analysis of using Danhong injection to treatment coronary heart disease patients medicines based on real world HIS database. Zhongguo Zhong Yao Za Zhi. 2011;36:2821–4.
    1. Chen Y, Liu M, Zhao T, Zhao B, Jia L, Zhu Y, et al. Danhong injection inhibits the development of atherosclerosis in both Apoe−/− and Ldlr−/− mice. J Cardiovasc Pharmacol. 2014;63:441–52. doi: 10.1097/FJC.0000000000000067.
    1. Chen J, Deng J, Zhang Y, Yang J, He Y, Fu W, et al. Lipid-lowering effects of Danhong injection on hyperlipidemia rats. J Ethnopharmacol. 2014;154:437–42. doi: 10.1016/j.jep.2014.04.023.
    1. Deng W, Yang C, Xiong M, Fu X, Lai H, Huang W. Danhong enhances recovery from residual dizziness after successful repositioning treatment in patients with benign paroxysmal positional vertigo. Am J Otolaryngol. 2014;35:753–7. doi: 10.1016/j.amjoto.2014.07.001.
    1. The medical society of Cardiology branch, editorial board of Chinese Journal of cardiovascular disease Chinese Guidelines for the Diagnosis and Treatment of Chronic Stable Angina. Zhonghua Xin Xue Guan Bing Za Zhi. 2007;35:195–206.
    1. Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-—summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina) Circulation. 2003;107:149–58. doi: 10.1161/01.CIR.0000047041.66447.29.
    1. Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F, et al. Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. 2006;27:1341–81. doi: 10.1093/eurheartj/ehl001.
    1. Zheng X. Guidelines of Clinical Research of New Drugs of Traditional Chinese Medicine. Beijing: China Medical Science Press; 2002.
    1. Spertus JA, Winder JA, Dewhurst TA, Deyo RA, Prodzinski J, McDonell M, Fihn SD. Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease. J Am Coll Cardiol. 1995;25:333–41. doi: 10.1016/0735-1097(94)00397-9.
    1. Spertus JA, Winder JA, Dewhurst TA, Deyo RA, Fihn SD. Monitoring the quality of life in patients with coronary artery disease. Am J Cardiol. 1994;74:1240–4. doi: 10.1016/0002-9149(94)90555-X.
    1. Spertus JA, Jones P, McDonell M, Fan V, Fihn SD. Health status predicts long-term outcome in outpatients with coronary disease. Circulation. 2002;106:43–9. doi: 10.1161/01.CIR.0000020688.24874.90.
    1. Zhang Z, Mahoney EM, Stables RH, Booth J, Nuqara F, Spertus JA, et al. Disease-specific health status after stent-assisted percutaneous coronary intervention and coronary artery bypass surgery: one-year results from the Stent or Surgery trial. Circulation. 2003;108:1694–700. doi: 10.1161/01.CIR.0000087600.83707.FD.
    1. Wyrwich KW, Spertus JA, Kroenke K, Tierney WM, Babu AN, Wolinsky FD. Clinically important differences in health status for patients with heart disease: an expert consensus panel report. Am Heart J. 2004;147:615–22. doi: 10.1016/j.ahj.2003.10.039.
    1. Weintraub WS, Spertus JA, Kolm P, Maron DJ, Zhang Z, Jurkovitz C, et al. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med. 2008;359:677–87. doi: 10.1056/NEJMoa072771.
    1. Yu Y, Hu S, Li G, Xue J, Li Z, Liu X, et al. Comparative effectiveness of Di’ao Xin Xue Kang capsules and compound Danshen tablet in patients with symptomatic chronic stable angina. Sci Rep. 2014;4:7058. doi: 10.1038/srep07058.
    1. Hao PP, Jiang F, Chen YG, Yang J, Zhang K, Zhang MX, et al. Traditional Chinese medication for cardiovascular disease. Nat Rev Cardiol. 2015;12:115–22. doi: 10.1038/nrcardio.2014.177.
    1. Xiong XJ, Wang PQ, Li XK, Zhang YQ. Effects of traditional Chinese patent medicine on essential hypertension: a systematic review. Medicine. 2015;94(e442):1–15.
    1. US Food and Drug Administration. Guidance, Compliance & Regulatory Information (Biologics).
    1. Cirulli J, McMillian WD, Saba M, Stenehjem D. Adaptive trial design: its growing role in clinical research and implications for pharmacists. Am J Health Syst Pharm. 2011;68:807–13. doi: 10.2146/ajhp100298.
    1. He ZQ, Ji RZ, Wang X, Liang C, Wu ZG. Effect of advanced glycation end products on the function and angiogenesis of adipose tissue-derived stem cells and the protective effect of Danhong injection: an experimental study. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2014;34:839–45.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する